A phase I and pharmacokinetic study to determine the safety of ET-743 administered as a continuous intravenous infusion over 24 hours every 21 days in patients with soft tissue sarcoma.
Phase 1
- Conditions
- Soft tissue sarcoma
- Registration Number
- JPRN-jRCT2080221134
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1)Patients who have a histologically confirmed soft tissue sarcoma.
2)Patients who have failed the standard therapy.
3)Others.
Exclusion Criteria
1)Serious concomitant illness.
2)Prior therapy-related toxicity.
3)Others.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Pharmacokinetics, Safety, Efficacy